News2022-09-15T16:59:10+00:00

News

Latest News

Latest News

About Armonica Technologies

Armonica Technologies is an Albuquerque, NM based biotechnology company focused on developing a proprietary long-read DNA sequencing technology. Armonica’s technology, optical nanopore sequencing, uses proprietary nanochannels to deliver long, individual single strand DNA molecules through nanopores to proprietary Surface Enhanced Raman Spectroscopy enhancement structures, where characteristic optical “fingerprint” signatures are read. Armonica’s approach will lead to faster, higher throughput and more accurate long-read genomic analysis than is currently available, without the need for extensive workflow and reagents

Contact Information

info@armonicatech.com

(505) 391-1812

Previous News

Armonica Technologies Awarded NIH Grant

Armonica Technologies, Inc., a biotechnology company developing a novel DNA sequencing system based on single molecule spectroscopy, announced that the company has been awarded a follow-on Phase II SBIR grant from the NIH’s National Human Genome Research Institute for “Single molecule DNA/RNA transport and Raman scattering readout in a coupled nanochannel/nanopore sequencing system.”  The award of $2M is in support of the company’s single molecule long read sequencing technology that detects all nucleic acid molecules including any chemical or conformational modifications.

The company’s CSO Steve Brueck said, “long-read, single-molecule, label-free sequencing that directly reads native DNA including epigenetic modifications, is considered the ultimate solution for DNA sequencing research and clinical applications.  Armonica’s unique technology provides the exciting capability to read the optical spectra, or ‘spectral fingerprint,’ of individual nucleotides, including any epigenetic modifications.  Measurements are made at the single molecule level using surface-enhanced Raman scattering.”  As part of the award, Armonica is partnering with Professor Jeremy Edwards’ high-throughput DNA sequencing laboratory (University of New Mexico, Chemical and Chemical Biology Department), as well as Professor Eric Potma’s laboratory for Chemical and Biological Imaging (University of California-Irvine, Chemistry Department).

Armonica has demonstrated the ability to linearize and control the motion of single large molecules of single and double strand DNA and has demonstrated single base sensitivity using a proprietary SERS approach that is inexpensively integrated with its nanochannel/nanopore devices.

The company’s CEO, Victor Esch, stated, “There continues to be a significant unmet research and clinical need for a simple, fast and accurate sequencing technology that can detect all pertinent DNA modifications. We are honored that the NIH has awarded us this Phase II, based on our technical accomplishments and the unique potential of our technology- unique in its approach and capabilities.  Our goal is to commercialize our system so that clinicians and researchers can measure all physical properties of genomic molecules.”

Armonica’s proprietary platform addresses the fundamental challenges involved with pore-based sequencing technologies, such as low throughput and limited accuracy, by naturally controlling the speed of nucleic acid transport through nanochannels and reading single base spectra optically, without the need for library preparations or biological manipulation. Armonica’s optical readout technology is label free, has massively parallel capabilities, and directly detects epigenetic nucleotide modifications. This unique approach will enable long-read sequencing and provide life science researchers with a powerful tool that can detect presently inaccessible nuances and provide more accurate identification of genome variations.

August 16, 2022|

Armonica Technologies Closes Additional Funding Round

Armonica Technologies, Inc., a biotechnology company developing a high throughput, direct long-read DNA sequencing technology, announced that it has raised $2M in new funding.  The financing included Hamamatsu Photonics K.K. and current investors Cottonwood Technology Fund, Sun Mountain Capital and Tramway Venture Partners. The funding will support further feasibility demonstration of company’s sequencing technology.

Akira Hiruma, President and CEO of Hamamatsu Photonics K.K., said, “At Hamamatsu, we are excited about our investment in Armonica, and their novel nanopore optical spectroscopy with its potential of new genetic sequencing methods to areas such as precision medicine. By investing in Armonica’s technology we hope to speed the development of new and more effective treatments to some of the world’s most devastating diseases.”

The Company’s CEO, Victor Esch, Ph.D. stated, “There continues to be an unmet clinical need for fast, high throughput long-read sequencing of native DNA, with an efficient workflow, that accurately identifies variants and epigenetics to enable clinical applications.  We are very excited about the progress the company has made in key areas of our technology, including the measurement of single nucleotide spectra.”

Armonica’s proprietary platform solves the fundamental challenges involved with traditional sequencing methodology, such as low speed and limited accuracy, by naturally controlling the speed of nucleic acid transport through nanochannels and reading single bases optically, without the need for library prep or adding biological constructs. Armonica’s optical readout technology is label free, has massive parallel capabilities, and can measure all epigenetic modifications directly. This unique approach to long-read sequencing will provide clinicians and researchers with a powerful tool that can detect previously unseen nuances and provide more accurate identification of genome variations and abnormalities.

October 8, 2021|

Armonica Technologies Awarded NIH Grant

Armonica Technologies, Inc., a biotechnology company developing a novel DNA sequencing system based on nano-structure devices, announced that the company has been awarded an SBIR grant from the NIH’s National Human Genome Research Institute for “Single molecule DNA/RNA transport and Raman scattering readout in a coupled nanochannel/nanopore sequencing system.” The award of $350K is in support of the company’s single molecule sequencing technology aimed at long read sequencing of large DNA molecules.

The company’s CSO Steve Brueck said, “long-read single-molecule sequencing that directly reads native DNA with epigenetic modifications, is considered the ideal solution for DNA sequencing research and clinical applications. Armonica’s unique technology is label and amplification free, and provides the exciting capability to read the optical spectra, or ‘spectral fingerprint’, of individual nucleotides including any epigenetic modifications.” As part of the award, Armonica is partnering with University of New Mexico through Jeremy Edwards’ high-throughput DNA sequencing laboratory in the department of Chemistry and Chemical Biology.

Armonica has demonstrated the ability to linearize and control the motion of single large molecules of single and double strand DNA, and has demonstrated single base sensitivity using a proprietary surface-enhanced Raman scattering (SERS) approach that is inexpensively integrated with its nanochannel/nanopore devices.

The company’s CEO, Victor Esch, stated, “Armonica continues to make significant improvements to the performance of our groundbreaking technology, and we are honored that the NIH has awarded us this grant in support of our product development goals.”

Armonica’s proprietary platform addresses the fundamental challenges involved with pore-based sequencing technologies, such as low throughput and limited accuracy, by naturally controlling the speed of nucleic acid transport through nanochannels and reading single base spectra optically, without the need for library preparations or biological manipulation. Armonica’s optical readout technology is label free, has massively parallel capabilities, and directly detects epigenetic nucleotide modifications. This unique approach will enable long-read sequencing and provide life science researchers with a powerful tool that can detect presently inaccessible nuances and provide more accurate identification of genome variations

March 17, 2021|
Go to Top